Program
sarecycline
Also written as “Sarecycline”, “50 mg P005672-HCl” and “100 mg P005672-HCl”.
Its studies are mostly in Acne Vulgaris, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Almirall | 40 open or running | phase 3since Dec 15, 2014 | Jun 22, 2012 | none ahead |
| Integrative Skin Science and Research | 11 open or running | phase 4since Apr 15, 2026 | Apr 15, 2026 | Apr 2027phase 4 · NCT07544251 |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2012First study: phase 2 study in Acne VulgarisNew to AlmirallAlmirall · NCT01628549 · 285 enrolled · United States
- Dec 15, 20142 phase 3 studies in Acne VulgarisAlmirall · NCT02322866, NCT02320149
- Apr 2, 2015Phase 3 study in Acne VulgarisAlmirall · NCT02413346 · 490 enrolled · United States
- Apr 15, 2026Integrative Skin Science and Research's first study: phase 4 study in Acne VulgarisNew to Integrative Skin Science and ResearchIntegrative Skin Science and Research · NCT07544251 · 30 planned · United States
Ahead
- Apr 2027Primary completion: phase 4 study in Acne VulgarisIntegrative Skin Science and Research · NCT07544251
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07544251Acne Vulgaris · United States | 4 | Recruiting | Integrative Skin Science and Research | Apr 2027 | 30 |
| NCT02413346Acne Vulgaris · United States | 3 | Completed | Almirall | Aug 26, 2016 | 490 |
| NCT02322866Acne Vulgaris · United States | 3 | Completed | Almirall | Jan 12, 2017 | 1,034 |
| NCT02320149Acne Vulgaris · United States | 3 | Completed | Almirall | Feb 1, 2017 | 968 |
| NCT01628549Acne Vulgaris · United States | 2 | Completed | Almirall | Nov 16, 2012 | 285 |
How it is read
Names in the registry
- “Sarecycline”, 4 entries
- “50 mg P005672-HCl”, 1 entry
- “100 mg P005672-HCl”, 1 entry
Conditions, from the studies’ own filings
- Acne Vulgaris, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.